Symrise presents new clinical data for Acerowell and postbiotic Rham271h

Symrise will show new clinical evidence at SupplySide Global 2026 in Las Vegas (booth 2364) for Acerowell, its vertically integrated acerola-based beauty-from-within ingredient, and for the postbiotic Rham271h, derived from inactivated Lacticaseibacillus rhamnosus 6594. Acerowell improved skin radiance and translucency versus placebo at 600 mg daily for 12 weeks in 108 women aged 45 to 60. LP299V and LPGOS42 dual-strain data showed significant gains in digestive comfort and regularity in an eight-week study of 100 adults.

Key facts

Market context

Acerola-derived ingredients and probiotic or postbiotic cultures are used in dietary supplements, functional foods, beverages, powders and gummies, where formulators look for ingredients backed by human clinical trials. Beauty-from-within products aim to support skin appearance, while digestive health formulations target comfort and regularity, two of the largest consumer categories for nutraceutical ingredients. Demand is shaped by consumer interest in preventive wellness, sports and active nutrition, and women's health. Postbiotics, which are made from inactivated bacteria, are attractive to manufacturers because they avoid the storage and viability constraints of live probiotic cultures while still offering functional claims. Competition in this segment depends on proprietary strains, documented efficacy and the ability to supply consistent material at scale. Partnerships that pair botanical actives with probiotic technology can broaden a supplier's portfolio and make it harder for single-ingredient rivals to win formulation slots.

Source: official release on symrise.com. Summary and context written by Market Krystal.